AzTrials
AzTrials

HIV PreventionSIIPANCT03278990

Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves

A study testing Value Affirmation and Future Selves Combination in people with HIV Prevention, run by Stuart Fisk at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Pre-exposure prophylaxis, or PrEP, is a relatively new HIV prevention method where individuals who are at risk for HIV but do not currently have it take a daily pill (Truvada). PrEP has been proven medically effective and could help to reduce the rate of new HIV incidence in the United States, but in five large… Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
HIV Prevention
What is being tested?
Value Affirmation and Future Selves Combination
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
26 participants
Where
1 siteUnited States
Study dates
19 Dec 2018to 16 Dec 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • HIV- men and women, age 18 and higher, who are seeking PrEP and deemed appropriate per local site investigator following the CDC risk indication guidelines for PrEP.
  • Must fit into one of the study's CDC-identified risk strata: a) IDUs and/or b) Caucasian LGBTQ or Minority LGBTQ
  • Must be able to read and write English for themselves.

Who cannot join

  • Same as that for PrEP initiation, e.g., existing HIV+ diagnosis or contra-indications, creatinine GFR < 60.
  • Current or previous use of PrEP.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Center for Inclusion Health, Allegheny General Hospital

    Pittsburgh, Pennsylvania, 15212

Other trials in United States

About this study

Official title: A Test of Scalable Behavioral Interventions to Increase PrEP Adherence for At-Risk HIV- Individuals: Value Affirmation and Future Selves

Pre-exposure prophylaxis, or PrEP, is a relatively new HIV prevention method where individuals who are at risk for HIV but do not currently have it take a daily pill (Truvada). PrEP has been proven medically effective and could help to reduce the rate of new HIV incidence in the United States, but in five large, randomized and controlled studies, many prospective PrEP patients chose not to take PrEP, and those that did often did not adhere to it consistently. How do we increase PrEP uptake and adherence amongst those most at risk for HIV? Also, will taking PrEP increase or decrease high-risk individual sexual behavior and HIV incidence? Here, the investigators propose a parallel group randomized, controlled clinical trial to test the effectiveness of a behavioral intervention designed to buffer individuals against stigma-related feelings, and to increase their connection to their selves twenty years in the future. The primary objective of the study is to increase PrEP adherence, as measured by the concentration of tenofovir diphosphate (TFV-DP) in dried blood spot samples (DBS). The secondary objectives are to decrease the incidence of STIs and increase safe sexual practices, as measured by clinic diagnoses and self-reported practices at 3, 6, 9 and 12 months.

This 12-month outpatient study will take place at four PrEP clinics in Pittsburgh and will enroll 170 subjects across 4 sites, with an expectation of retaining 80%, or 135 subjects. Eligibility includes male and female adults, ages 18-65, who are at risk of contracting HIV. Efforts will be made to recruit 33% of subjects from each of the following strata: 1) young, minority LGBT adults age 18-30 years of age; 2) Caucasian adults (MSM and heterosexual females) age 18-65 years of age; and 3) IDU adults, age 18-65, of any ethnic background.

Read the detailed description

Pre-exposure prophylaxis, or PrEP, is a relatively new HIV prevention method where individuals who are at risk for HIV but do not currently have it take a daily pill (Truvada). The CDC currently recommends PrEP as a method of HIV prevention in high-risk individuals based on compelling efficacy data from large international studies in diverse populations, but the issue of adherence and its relationship to clinical efficacy is still being defined. In five large, randomized and controlled studies, many prospective PrEP patients chose not to take PrEP, and those that did often did not adhere to it consistently (Landovitz \& Coates, 2014). Experts remain unable to answer several high-stakes questions: How do we increase PrEP uptake and adherence amongst those most at risk for HIV, and will starting PrEP increase or decrease high-risk individual sexual behavior and HIV incidence? (Landovitz \& Coates, 2014). In sum, the biggest challenge to reducing new HIV incidence in the U.S. is behavioral, not medical.

Here, the investigators propose a randomized, controlled clinical study to test the effectiveness of a "future selves-value affirmation" behavioral intervention on PrEP uptake and adherence. The intervention is designed to address the challenges of stigma and "present bias" - the individual propensity to place the gains of the moment ahead of future gains- as it relates to adherence.

"Present bias" and the suboptimal decisions it produces derive from a limited ability to imagine one's self in the future, and lead to a patient's preference for smaller, immediate rewards (e.g., escaping side effects of a medication, safeguarding one's situation from loved ones) over larger, delayed ones (e.g., not contracting HIV, longer life expectancy, better health). Research has shown that vivid, concrete, and detailed images of one's future self enhance a person's ability to envision and emotionally engage the future consequences of present-day decisions. For instance, creating positive images of one's future self has been shown to stem delinquent behavior for up to a year (van Gelder, 2013).

To address stigma, the investigators draw on another literature in psychology which has now established that short value affirmation exercises are able to enhance learning, performance, control and commitment outcomes, and to do so most effectively with populations facing stigma in the domain of interest (Vohs \& Smeichel, 2009; Creswell et al., 2013; Creswell \& Lindsay, 2014), especially within the domain of health behavior change (Ehret \& Sherman, 2014; Harris, 2011; Reed \& Aspinwall, 1998; Nustad, 2011; Cohen and Sherman, 2014; Epton et al., 2015). Affirmation exercises can be as simple as writing or talking for 5 minutes about a value one holds dear. Indeed, one such 5-minute exercise at the beginning of a new program or project can lead to profoundly powerful long-term outcomes across very different settings. For example, one intervention led to a .41 point grade increase for minority students in college over the course of one and two years (Cohen et al, 2009), increased decision making skills and use of public service information by homeless shelter participants in Seattle (Hall et al., 2014), and enabled smokers to more readily accept threatening smoking risk information (Epton et al., 2015). This study will combine value affirmation and future selves approaches.

The first study objective is to evaluate the effect of the "future-selves / value affirmation" intervention on PrEP adherence, as measured by tenofovir levels in dried blood spots and categorized via the 5-level ordinal measure for Engagement with PrEP (used in the iPrEx Open-Label Extension). The secondary study objectives are to evaluate the effect of the "future-selves / value affirmation" intervention on HIV and STI contraction at 3, 6, 9, and 12 months, and to evaluate the effect of the "future-selves / value affirmation" intervention on sexual risk behaviors, as self-reported numbers of anal/vaginal sex partners and episodes of condomless receptive anal and vaginal sex at 3, 6, 9 and 12 months.

This is a parallel group randomized trial with 2 arms-a control arm with allocation ratio of 50%, and an intervention arm (future self-value affirmation) with an allocation ratio of 50%. At each clinic visit, participants will engage in a 10-minute writing (or oral, for those with literacy challenges) exercises. Participants in the intervention arm will be given a list of values, asked to select one that has been particularly important to them at critical times in their life, then asked to write about why that value is important to them. Next, those same participants will write a letter to themselves twenty (20) years in the future. Participants in the control arm will first write for 5 minutes about why two values that are least important to them may be important to someone else, and next write a letter to themselves two weeks in the future.

The study includes 170 subjects enrolled across 4 sites in Pittsburgh, with an expectation of retaining 80%, or 135 subjects. Each subject's participation will last for 12 months.The entire study is expected to last for 18 months. The investigators will evaluate concentrations of tenofovir diphosphate (TFV-DP) in dried blood spot samples at baseline and then quarterly visits; they will also perform quarterly evaluations of self-reported numbers of anal/vaginal sex partners and episodes of condomless receptive anal and vaginal sex with and without condoms; incidence of STI and HIV acquisition.

The investigators will employ a mixed ANOVA to look at intervention effects on adherence-as well as STI incidence, and safe sex practices-across time intervals. They will also estimate mixed regression models for the intervention.

Conditions
HIV Prevention
Being tested
Value Affirmation and Future Selves Combination, Control writing exercise
Keywords
PrEP, Prevention, Value Affirmation, Future Selves, Behavioral Intervention

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Value Affirmation and Future Selves CombinationBehavioural

    Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.

  • Control writing exerciseBehavioural

    In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.

Study groups in NCT03278990
Study groupRoleWhat they receive
Future Self - Value AffirmationExperimentalThis is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
Receives: Behavioral: Value Affirmation and Future Selves Combination
ControlSham comparatorIn this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
Receives: Behavioral: Control writing exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. PrEP Adherence

    Tenofovir concentrations in dried blood spots

    Measured: quarterly, for one year

Secondary outcomes (4)
  1. HIV contraction

    Diagnosis of HIV throughout the study period

    Measured: quarterly, for one year

  2. Sexual Risk Behavior 1: Partners

    Number of Partners in anal or vaginal sex

    Measured: quarterly, for one year

  3. Sexual risk behavior 2: Condomless sex

    number of condomless vaginal or anal sex occurrences

    Measured: quarterly, for one year

  4. STI contraction

    Diagnosis of an STI throughout the study period

    Measured: quarterly, for one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2017
  2. Study start19 Dec 2018
  3. Primary completion16 Dec 2020
  4. Study completion16 Dec 2020

Why it stopped: Did not meet recruitment goals

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a parallel group randomized trial with 2 arms-a control arm with allocation ratio of 50%, and an intervention arm (future self-value affirmation) with an allocation ratio of 50%.
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
26 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03278990
Sponsor's protocol ID
IN-US-276-4221
Acronym
SIIPA
Status last verified
Oct 2021
First submitted
7 Sep 2017
Last updated
11 Oct 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Only de-identified information will be shared regarding STI/HIV diagnosis.

Questions about this trial

What is this clinical trial studying?

A study testing Value Affirmation and Future Selves Combination in people with HIV Prevention, run by Stuart Fisk at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 11 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Did not meet recruitment goals). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

PrEP Adherence (time frame: quarterly, for one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in